MDXG vs. AORT, FNA, ATRC, KIDS, ATRI, SILK, TMCI, SIBN, EMBC, and NVCR
Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Artivion (AORT), Paragon 28 (FNA), AtriCure (ATRC), OrthoPediatrics (KIDS), Atrion (ATRI), Silk Road Medical (SILK), Treace Medical Concepts (TMCI), SI-BONE (SIBN), Embecta (EMBC), and NovoCure (NVCR). These companies are all part of the "surgical & medical instruments" industry.
Artivion (NYSE:AORT) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.
Artivion currently has a consensus target price of $23.50, suggesting a potential upside of 14.24%. MiMedx Group has a consensus target price of $12.25, suggesting a potential upside of 94.14%. Given Artivion's higher possible upside, analysts clearly believe MiMedx Group is more favorable than Artivion.
MiMedx Group has lower revenue, but higher earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Artivion has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.
In the previous week, MiMedx Group had 4 more articles in the media than Artivion. MarketBeat recorded 7 mentions for MiMedx Group and 3 mentions for Artivion. Artivion's average media sentiment score of 0.56 beat MiMedx Group's score of 0.00 indicating that MiMedx Group is being referred to more favorably in the news media.
86.4% of Artivion shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 8.1% of Artivion shares are held by company insiders. Comparatively, 19.9% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
MiMedx Group received 20 more outperform votes than Artivion when rated by MarketBeat users. Likewise, 76.19% of users gave MiMedx Group an outperform vote while only 66.67% of users gave Artivion an outperform vote.
MiMedx Group has a net margin of 14.49% compared to MiMedx Group's net margin of -8.67%. Artivion's return on equity of 41.12% beat MiMedx Group's return on equity.
Summary
MiMedx Group beats Artivion on 14 of the 17 factors compared between the two stocks.
Get MiMedx Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiMedx Group Competitors List
Related Companies and Tools
